555 research outputs found
The Challenge of the Overactive Bladder: From Laboratory to New Drugs
No full textAntimuscarinic agents are currently the first-line therapy for overactive bladder (OAB). Many urologists believe the pharmacologic management of OAB is not altogether satisfactory. Pharmacologic research is trying to provide answers to the issues of efficacy, tolerability, and convenience of new drugs. This paper discusses the rationale underlying the development of new compounds, provides an update of progress in the search for new therapies for OAB, and tracks their translation into clinical practice. It offers an insight into the mechanism of action, efficacy, side-effects, and "market status" of several drug categories targeting the central nervous system (adrenoceptor modulators, serotonin/norepinephrine reuptake inhibitors, tachykinin modulators, opioids), neuromuscular blocking agents (botulinum toxin A), selective modulators of the afferent branch of micturition reflex (vanilloid, nociceptin/orphanin FQ), autonomic nervous system modulators (β3-agonists), potassium and calcium channel openers, and nonsteroidal anti-inflammatory drugs
Bladder stone formation after a tension-free vaginal tape procedure: Report on two cases - Commentary
No full textWe present 2 cases of large bladder stones formed on a tension-free vaginal tape (TVT) which was inadvertently passed through the bladder during the continence procedure. The stones together with the intravesical portion of the slings were removed using a suprapubic approach. High clinical suspicion of bladder complications is necessary when evaluating patients with urinary symptoms after a TVT operation
Pros and Cons of Focal Therapy for Localised Prostate Cancer
No full textIn prostate cancer, an interesting and intriguing option to overcome the risks of whole-gland treatment is focal therapy, with the aim of eradicating known cancer foci and reducing collateral damages to the structures essential for maintaining normal urinary and sexual function. Ablation of all known lesions would favorably alter the natural history of the cancer without impacting health-related quality of life and allows for safe retreatment with repeated focal therapy or whole-gland approaches if necessary. Our objective is to reassess the possibilities and criticisms of such procedure: the rationale for focal therapy and the enthusiasm come from the success of conservative approaches in treating other malignancies and in the high incidence of overtreatment introduced by prostate cancer screening programs. One of the challenges in applying such an approach to the treatment of prostate cancer is the multifocal nature of the disease and current difficulties in accurate tumor mapmaking
- …
